Zoll Medical Corporation (NasdaqGS: ZOLL) announced today that in a
"Best of the Best” presentation at the American Heart Association
Resuscitation Science Symposium in Orlando Florida, Daniel P. Davis,
M.D., presented research from the University of California Resuscitation
Research Center that shows a major improvement in patient outcome after
cardiac arrest.
Dr. Davis stated, "Since the implementation of the program in 2007,
patients at the hospital are three times more likely to survive an
unexpected cardiac arrest and twice as likely to survive with good
neurological outcome than was possible before this new initiative.” The
program consists of a number of elements including a new and innovative
Advanced Resuscitation Training program, a new and novel in-patient
treatment algorithm, education, a rapid response team, and new
technology to improve pre-, intra- and post- resuscitation care and
process, according to Dr. Davis.
The program utilizes a number of technological innovations provided in
ZOLL equipment used system-wide in the University of California San
Diego Hospitals, where Dr. Davis is Director of Resuscitation. Specific
capabilities of the equipment relate to monitoring and improving CPR
performance and process. All of the ZOLL E Series® monitor
defibrillators used for resuscitation at UCSD include Real CPR Help®
real-time feedback; See Thru CPR®, industry-unique filtering
technology that allows clinicians to view a patient’s underlying cardiac
rhythm by filtering CPR artifact during resuscitation efforts; and
sidestream and mainstream ETCO2 monitoring capability. ZOLL’s CodeNet®
software collects all resuscitation and CPR process data when a
resuscitation event occurs and permits the post-event review of the
entire resuscitation event and process.
Dr. Davis reported high compliance with goals for the provisioning of
adequate chest compression rate and depth, reduction of pre- and post-
shock interruptions to CPR, shortened pulse check pauses, and better
coordination of compressions and ventilations. Rescuers achieved a 91%
CPR fraction with the new protocols and ZOLL See-Thru CPR and the CPR
feedback, and measurement provided by Real CPR Help. Data recorded
during resuscitations demonstrated CPR rates at 123 compressions per
minute on average and an average depth of 2.6 inches. Pauses during CPR
were significantly shortened to less than five seconds for any reason,
and the incidence of immediate CPR on discovery of an arrest was
improved as well after the training.
"We are very pleased about the report from UCSD and confident the
improvements reported by Dr. Davis can be realized in many other
hospitals and EMS operations that select ZOLL products,” said Jonathan
A. Rennert, President of ZOLL. "We are very committed to helping
agencies translate these unique ZOLL technologies into meaningful
improvement in outcomes from cardiac arrest.”
About ZOLL Medical Corporation
ZOLL Medical Corporation develops and markets medical devices and
software solutions that help advance emergency care and save lives,
while increasing clinical and operational efficiencies. With products
for defibrillation and monitoring, circulation and CPR feedback, data
management, fluid resuscitation, and therapeutic temperature management,
ZOLL provides a comprehensive set of technologies which help clinicians,
EMS and fire professionals, and lay rescuers treat victims needing
resuscitation and critical care.
A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company
for the past three years, ZOLL develops and manufactures its products in
the United States, in California, Colorado, Illinois, Massachusetts,
Pennsylvania, and Rhode Island. More than 400 direct sales and service
representatives, 1,100 business partners, and 200 independent
representatives serve our customers in over 140 countries around the
globe. For more information, visit www.zoll.com.
Certain statements contained in this press release, including
statements regarding the future business of the Company, and other
statements contained herein regarding matters that are not historical
facts, are "forward-looking” statements (as defined in the Private
Securities Litigation Reform Act of 1995). Because such statements are
subject to risks and uncertainties, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Factors that could cause actual results to differ materially from those
expressed or implied by such forward-looking statements include, but are
not limited to, those factors discussed in the section entitled "Risk
Factors” in the Company's Quarterly Report on Form 10-Q filed with the
SEC on August 7, 2009. You should not place undue reliance on the
forward-looking statements in this press release, and the Company
disavows any obligation to update or supplement those statements in the
event of any changes in the facts, circumstances, or expectations that
underlie those statements.
Copyright © 2009 ZOLL Medical Corporation. All rights reserved. 269 Mill
Road, Chelmsford, MA 01824-4105. ZOLL, CodeNet, E Series, Real CPR Help,
and See-Thru CPR are registered trademarks of ZOLL Medical Corporation.
